Cargando…
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the rel...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418566/ https://www.ncbi.nlm.nih.gov/pubmed/22551397 http://dx.doi.org/10.1186/1471-2407-12-162 |
_version_ | 1782240649292021760 |
---|---|
author | Ueno, Daiki Yao, Masahiro Tateishi, Ukihide Minamimoto, Ryogo Makiyama, Kazuhide Hayashi, Narihiko Sano, Futoshi Murakami, Takayuki Kishida, Takeshi Miura, Takeshi Kobayashi, Kazuki Noguchi, Sumio Ikeda, Ichiro Ohgo, Yoshiharu Inoue, Tomio Kubota, Yoshinobu Nakaigawa, Noboru |
author_facet | Ueno, Daiki Yao, Masahiro Tateishi, Ukihide Minamimoto, Ryogo Makiyama, Kazuhide Hayashi, Narihiko Sano, Futoshi Murakami, Takayuki Kishida, Takeshi Miura, Takeshi Kobayashi, Kazuki Noguchi, Sumio Ikeda, Ichiro Ohgo, Yoshiharu Inoue, Tomio Kubota, Yoshinobu Nakaigawa, Noboru |
author_sort | Ueno, Daiki |
collection | PubMed |
description | BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG PET/CT to long-term prognosis with an expanded number of patients and period of observation. METHODS: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment to progression free survival (PFS) and overall survival (OS) were investigated. RESULTS: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271) and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases) were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased<20% was shorter than that of the patients whose SUVmax decreased<20% (P = 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448). The patients were classified into three response groups: good responder (diameter sum did not increase, and SUVmax decreased ≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased<20%), and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good, intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate P = 0.0366, intermediate vs. poor P = 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days, 469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P = 0.0385, intermediate vs. poor P = 0.0305, log-rank test). CONCLUSIONS: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after 1 month can predict PFS and OS. |
format | Online Article Text |
id | pubmed-3418566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34185662012-08-15 Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course Ueno, Daiki Yao, Masahiro Tateishi, Ukihide Minamimoto, Ryogo Makiyama, Kazuhide Hayashi, Narihiko Sano, Futoshi Murakami, Takayuki Kishida, Takeshi Miura, Takeshi Kobayashi, Kazuki Noguchi, Sumio Ikeda, Ichiro Ohgo, Yoshiharu Inoue, Tomio Kubota, Yoshinobu Nakaigawa, Noboru BMC Cancer Research Article BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG PET/CT to long-term prognosis with an expanded number of patients and period of observation. METHODS: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment to progression free survival (PFS) and overall survival (OS) were investigated. RESULTS: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271) and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases) were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased<20% was shorter than that of the patients whose SUVmax decreased<20% (P = 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448). The patients were classified into three response groups: good responder (diameter sum did not increase, and SUVmax decreased ≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased<20%), and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good, intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate P = 0.0366, intermediate vs. poor P = 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days, 469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P = 0.0385, intermediate vs. poor P = 0.0305, log-rank test). CONCLUSIONS: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after 1 month can predict PFS and OS. BioMed Central 2012-05-02 /pmc/articles/PMC3418566/ /pubmed/22551397 http://dx.doi.org/10.1186/1471-2407-12-162 Text en Copyright ©2012 Ueno et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ueno, Daiki Yao, Masahiro Tateishi, Ukihide Minamimoto, Ryogo Makiyama, Kazuhide Hayashi, Narihiko Sano, Futoshi Murakami, Takayuki Kishida, Takeshi Miura, Takeshi Kobayashi, Kazuki Noguchi, Sumio Ikeda, Ichiro Ohgo, Yoshiharu Inoue, Tomio Kubota, Yoshinobu Nakaigawa, Noboru Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title_full | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title_fullStr | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title_full_unstemmed | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title_short | Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
title_sort | early assessment by fdg-pet/ct of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418566/ https://www.ncbi.nlm.nih.gov/pubmed/22551397 http://dx.doi.org/10.1186/1471-2407-12-162 |
work_keys_str_mv | AT uenodaiki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT yaomasahiro earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT tateishiukihide earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT minamimotoryogo earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT makiyamakazuhide earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT hayashinarihiko earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT sanofutoshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT murakamitakayuki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT kishidatakeshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT miuratakeshi earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT kobayashikazuki earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT noguchisumio earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT ikedaichiro earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT ohgoyoshiharu earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT inouetomio earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT kubotayoshinobu earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse AT nakaigawanoboru earlyassessmentbyfdgpetctofpatientswithadvancedrenalcellcarcinomatreatedwithtyrosinekinaseinhibitorsispredictiveofdiseasecourse |